Encrypgen is genetic processing software that promises to empower patients and donors while facilitating health, business, and science in a safe environment. Here’s our review.
What Is Encrypgen?
Encrypgen is a blockchain technology company that aims to bring the benefits of blockchain technology to genomic research. The company is currently seeking beta deployments.
Encrypgen, LLC is based in Coral Springs, Florida. The company was founded by author and philosopher David Koepsell.
Essentially, Encrypgen will use a platform called the Gene-Chain to give patients greater control over their genetic data. Patients will be able to use the Gene-Chain to control access to their genetic data.
They can choose to share their genome with genetic researchers, for example, or make certain parts of their genome available to medical professionals.
The other benefit of Encrypgen, of course, is privacy. How can companies use your genetic data? Can they sell your genetic data? Can your genetic data be used in legal cases? Can an employer request your genetic data?
The blockchain could solve these problems by putting patients in control of their own genetic data.
Encrypgen recently launched its ICO. The company is offering various bonuses throughout June 2017. As of June 12, a purchase of 1 BTC or equivalent (in ETH, Dash, LTC, or ETC) will get you 76,000 Gene-Chain Coins. That amount will drop by 5% weekly.
What Is The Gene-Chain?
The core Encrypgen technology is the “Gene-Chain”. The company describes the product as “a solution for enhancing privacy, security, and utility in genomic databases.”
You can access the Gene-Chain using the company’s tokens, Gene-Chain Coins.
Using to the Gene-Chain, individuals can store genetic data securely while still sharing it with other individuals – like medical professionals or genetic testing companies.
The Gene-Chain Coin is the byproduct of hosting nodes on the Gene-Chain and mining per standard blockchain processes. The Gene-Chain Coin will also be available to the public through mining via passive nodes. You’ll be able to trade it in standard crypto markets.
Overall, Gene-Chain is a suite of software in active development. The software will allow individuals, hospitals, and laboratories to store and manage genomic data.
How Does The Gene-Chain Work?
The Gene-Chain is a blockchain that allows users to easily store their genetic data. You can get a genetic test, then store that data on the Gene-Chain. You can access that data at any time. The data is stored on the Gene-Chain free of charge.
Once it’s on the Gene-Chain, you can access your own data using your private keys. Your data is encrypted and virtually unhackable.
If you choose to share your genetic data with someone, you can provide a time-limited key to your doctor or anyone else with whom you need to share the data. You can also decide exactly which part of your genome you wish to share.
The Gene-Chain will also track misuse of that data. Each transaction has a unique signature.
The primary benefits of the Gene-Chain are obvious: users can securely store their genetic data, then choose who gets access to their data. It’s a secure way for individuals and corporations to share and access data in a world where more and more people are getting genetic tests.
Aside from these benefits, the biggest benefits of Encrypgen’s Gene-Chain will be seen in the field of genetic research.
Here’s where the Gene-Chain becomes important: people can choose to share their data for the purposes of genetic research. Scientists can access metadata – like age, ethnicity, and gender – and search for potential subjects who may have useful and interesting data.
That search reveals nothing specific or personal about the donor, and it doesn’t give them direct access to the genome itself. However, researchers can contact that donor, and request additional information from that individual. They can negotiate terms or even sell their data to researchers.
As company founder Dr. David Koepsell said in an interview with Forbes,
“All of this will mean a real revolution in genomic science, as well as provide donors of data with greater protection than ever. Blockchain also enables a lot of that functionality because one of its strengths, besides extremely strong encryption, is managing transactions. Research institutes and companies with large amount of genomic data can purchase licenses to store their data without worrying about the ethics, which is baked into the product and its transactions, allowing them to instead focus on the science.”
In other words, blockchain technology could change the genetic testing world as we know it.
The Encrypgen ICO
The ICO is underway through June and the start of July. You can take part in the ICO at the official Encrypgen website.
With the ICO, you can send any amount of BTC, ETH, Dash, LTC, or ETC to the addresses on the page above. Within 24 hours, you’ll receive a signed SAFT agreement. Wallets will be distributed when Encrypgen reaches its goal (currently set at 1,000 BTC).
Various bonuses are available. Right now, a 1 BTC purchase will give you 76,000 Gene-Chain Coins. That number will drop by 5% each week as the ICO goes on.
Purchases over 5 BTC will get 5% extra coins. The biggest overall purchaser over the course of the campaign will receive 1,000,000 extra Gene-Chain Coins. The current leading investor has contributed 9.2 BTC.
There’s a planned total supply of 100 million tokens. 80 million tokens will be sold in the sale. 10 million are reserved for the development team. 5 million are for marketing, and 5 million are for bonuses.
Encrypgen is based at the following address in Florida:
9900 West Sample Rd, Suite 300
Coral Springs, FL 33065
The company was founded by philosopher Dr. David Koepsell and his long-time collaborator and partner, Dr. Vanessa Gonzalez. Dr. Koepsell is the CEO and Dr. Gonzalez is listed as the Genomic Science Advisor.
Dr. Koepsell has been outspoken about the ownership and protection of genetic data for nearly a decade. In 2009, he published a book called Who Owns You, where he discussed the implications of corporations owning genetic data.
A few months after that book was published, the genetic testing industry participated in practices specifically outlined in the book. Genetic company Myriad Corporation filed patent requests on BRCA genes.
If that patent request was successful, Myriad would have been able to monopolize genetic testing for breast and ovarian cancer. The company eventually lost their patents due to challenges from the ACLU and other groups.
Dr. Koepsell left the world of academia to found Encrypgen. The company was founded in early 2017.
Encrypgen is a unique blockchain technology specifically targeted at the world of genetic research. It plans to make it easier for patients to manage their genetic data. Patients can use Encrypgen’s core platform, the Gene-Chain, to control access to their genetic data.
They can choose to share certain genetic data with researchers, for example, or show parts of the genome to medical professionals on request.
We live in a world where more and more people are getting genetic tests – but nobody really knows how to manage all of this data. Encrypgen’s Gene-Chain wants to solve that problem.
Stay tuned for more information about Encrypgen as the ICO continues to take place over the coming month.